Cardinal Health, Inc.'s Stock Analysis

Cardinal Health Announces Board Leadership Changes and Earnings Release

Gregory B. Kenny will retire from the Board of Directors and as Board Chair effective March 20, 2026. Patricia A. Hemingway Hall has been appointed as the new Board Chair immediately following Mr. Kenny's retirement. Mr. Kenny has been with the Board since 2007 and has played a significant role during his tenure, including overseeing strategic transformations. Ms. Hemingway Hall has been a director since 2013 and brings extensive healthcare leadership experience to her new role.

Cardinal Health will report its third quarter fiscal 2026 earnings on April 30, 2026. The company has expressed confidence in its outlook for fiscal 2026. Cardinal Health operates in various sectors, including pharmaceutical distribution and medical product manufacturing, and emphasizes a customer-centric approach aimed at continuous improvement and innovation.

Mar 23, 2026 06:48:23

Cardinal Health Chief Accounting Officer Plans Retirement in 2027

Mary Scherer, Senior Vice President and Chief Accounting Officer of Cardinal Health, has announced her intention to retire in February 2027. The company will begin the search for her successor, ensuring that she will remain in her role until the new appointee is identified and onboarded to facilitate a smooth transition.

This leadership change may impact the company's financial reporting and governance structure. Investors should monitor the progress of the succession plan and any potential effects on the company's operations during this transition period.

Mar 05, 2026 07:07:59

Cardinal Health Reports Revenue Growth and Raises EPS Guidance

Cardinal Health, Inc. announced a revenue increase of 19% to $65.6 billion for the second quarter of fiscal year 2026, compared to the same period in the previous year. GAAP operating earnings rose by 29% to $707 million, and GAAP diluted earnings per share (EPS) increased by 19% to $1.97. Non-GAAP operating earnings also saw a significant rise of 38% to $877 million, with non-GAAP diluted EPS growing by 36% to $2.63. The company noted strong segment profit growth across all five operating segments, particularly in the Pharmaceutical and Specialty Solutions segment, which experienced a 19% revenue increase driven by brand and specialty pharmaceutical sales growth.

In response to its strong performance, Cardinal Health raised its fiscal year 2026 guidance for non-GAAP diluted EPS to a range of $10.15 to $10.35, reflecting anticipated growth of 23% to 26%. The company also completed a $375 million accelerated share repurchase program during the quarter, bringing total share repurchases for the fiscal year to $750 million. Additionally, Cardinal Health achieved its targeted leverage range of 3.2x as of December 31, 2025, indicating a solid financial position.

Feb 05, 2026 06:47:19

Cardinal Health Raises Fiscal 2026 Earnings Outlook and Growth Plans

Cardinal Health has updated its fiscal year 2026 non-GAAP diluted earnings per share (EPS) outlook, raising it to at least $10.00 from the previous range of $9.65 to $9.85. This revision reflects strong performance across the company's five operating segments. Additionally, Cardinal Health anticipates that its Specialty revenues will exceed $50 billion in fiscal 2026, representing a 16% compounded annual growth rate over three years. The company attributes this growth to increased demand in specialty distribution and significant revenue growth in its BioPharma Solutions segment.

The company has successfully transitioned its manufacturer distribution agreements for branded pharmaceuticals in light of the 2026 Medicare Drug Price Negotiation Program. Cardinal Health also introduced the ContinuCare™ Pathway program to enhance diabetes supply management for patients and pharmacies, partnering with Publix Super Markets to expand this initiative. The company plans to further discuss its financial outlook and strategic initiatives during its upcoming earnings call on February 5, 2026.

Jan 13, 2026 06:53:33

Cardinal Health Annual Meeting Results and Shareholder Votes

Cardinal Health, Inc. held its 2025 Annual Meeting of Shareholders on November 5, 2025. During the meeting, shareholders elected 12 nominees to the Board of Directors, each serving until the 2026 Annual Meeting or until their successors are appointed. Additionally, shareholders approved a non-binding advisory vote on the compensation of the Company's named executive officers and ratified the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending June 30, 2026.

The results of the votes indicate shareholder support for the current leadership and compensation structure, which may influence investor confidence. The election of the board and the approval of the auditor are critical governance matters that can impact the company's operational direction and financial reporting, factors that may be relevant for investors monitoring Cardinal Health's performance.

Nov 06, 2025 16:13:37

Cardinal Health Reports 22% Revenue Growth in Q1 2026

Cardinal Health reported a revenue increase of 22% for the first quarter of fiscal year 2026, reaching $64 billion. GAAP operating earnings rose 18% to $668 million, while GAAP diluted earnings per share (EPS) increased 11% to $1.88. Non-GAAP operating earnings saw a 37% increase to $857 million, leading to a 36% rise in non-GAAP diluted EPS to $2.55. The company is also raising its fiscal year 2026 non-GAAP EPS guidance to a range of $9.65 to $9.85 and adjusted free cash flow outlook to $3.0 to $3.5 billion.

The Pharmaceutical and Specialty Solutions segment contributed significantly to this growth, with revenues climbing 23% to $59.2 billion, driven by brand and specialty pharmaceutical sales. The Global Medical Products and Distribution segment experienced a 2% revenue increase to $3.2 billion. Cardinal Health also anticipates completing the acquisition of Solaris Health in early November, which is expected to further enhance its operational capabilities. The company has initiated a $375 million accelerated share repurchase program in the first quarter, signaling a commitment to returning value to shareholders.

Oct 30, 2025 06:52:52

Cardinal Health Secures $1 Billion Credit Agreement for Operations

Cardinal Health, Inc. has entered into a new 364-Day Credit Agreement with Bank of America, providing access to $1.0 billion in revolving credit until October 6, 2026. This agreement follows the expiration of a previous credit agreement from October 2024 and allows for the conversion of outstanding loans into non-revolving term loans under specific conditions. The facility is intended for general corporate purposes and supports the company's commercial paper program.

The Credit Agreement includes a financial covenant requiring Cardinal Health to maintain a Consolidated Net Leverage Ratio of no greater than 3.75 to 1.00 at the end of each fiscal quarter. It also outlines customary representations, affirmative and negative covenants, and events of default. Financial institutions involved may provide additional services to the company, for which Cardinal Health pays customary fees.

Oct 10, 2025 06:33:04

Cardinal Health Extends Receivables Purchase Agreement to 2028

Cardinal Health has entered into an amendment to its receivables purchase agreement, extending the term of the facility until September 28, 2028. This agreement involves several financial institutions, including Wells Fargo Bank, Liberty Street Funding, and Bank of America, which have previously provided various banking services to the company.

The amendment is part of a broader arrangement that includes a $2.0 billion revolving credit facility, with multiple banks acting as members of the lending syndicate. The involvement of these financial institutions suggests ongoing support for Cardinal Health's financing needs, which may influence investor confidence.

Oct 03, 2025 06:25:39

Cardinal Health Raises $1 Billion Through Public Notes Offering

Cardinal Health, Inc. completed a public offering totaling $1 billion, comprising $600 million in 4.500% Notes due 2030 and $400 million in 5.150% Notes due 2035. The proceeds from this offering will primarily be used to fund the acquisition of Solaris Health, as well as cover associated fees and expenses. Until the proceeds are allocated for the acquisition, the company may use them for general corporate purposes.

The Notes are subject to a special mandatory redemption if the acquisition is not completed by August 12, 2026, or if the company decides not to pursue the acquisition. In such cases, the Notes will be redeemed at 101% of their principal amount, plus any accrued interest. The offering was conducted under an effective registration statement previously filed with the SEC, and the legal opinions regarding the issuance of the Notes were provided by the company’s counsel.

Aug 27, 2025 17:02:44

Cardinal Health Issues $1 Billion in New Notes Offering

Cardinal Health, Inc. has entered into an underwriting agreement to sell $600 million of 4.500% Notes due 2030 and $400 million of 5.150% Notes due 2035. This offering is conducted under the company's effective registration statement filed with the Securities and Exchange Commission.

The underwriting agreement involves Goldman Sachs & Co. LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC as representatives of the underwriters. A complete copy of the Underwriting Agreement is available as an exhibit in the current report.

Aug 14, 2025 17:06:21